A molecular map of lung neuroendocrine neoplasms.

Tumormap carcinoids genomics lung cancer lungNENomics project neuroendocrine neoplasms rare cancers

Journal

GigaScience
ISSN: 2047-217X
Titre abrégé: Gigascience
Pays: United States
ID NLM: 101596872

Informations de publication

Date de publication:
30 10 2020
Historique:
received: 21 01 2020
revised: 04 06 2020
entrez: 30 10 2020
pubmed: 31 10 2020
medline: 26 10 2021
Statut: ppublish

Résumé

Lung neuroendocrine neoplasms (LNENs) are rare solid cancers, with most genomic studies including a limited number of samples. Recently, generating the first multi-omic dataset for atypical pulmonary carcinoids and the first methylation dataset for large-cell neuroendocrine carcinomas led us to the discovery of clinically relevant molecular groups, as well as a new entity of pulmonary carcinoids (supra-carcinoids). To promote the integration of LNENs molecular data, we provide here detailed information on data generation and quality control for whole-genome/exome sequencing, RNA sequencing, and EPIC 850K methylation arrays for a total of 84 patients with LNENs. We integrate the transcriptomic data with other previously published data and generate the first comprehensive molecular map of LNENs using the Uniform Manifold Approximation and Projection (UMAP) dimension reduction technique. We show that this map captures the main biological findings of previous studies and can be used as reference to integrate datasets for which RNA sequencing is available. The generated map can be interactively explored and interrogated on the UCSC TumorMap portal (https://tumormap.ucsc.edu/?p=RCG_lungNENomics/LNEN). The data, source code, and compute environments used to generate and evaluate the map as well as the raw data are available, respectively, in a Nextjournal interactive notebook (https://nextjournal.com/rarecancersgenomics/a-molecular-map-of-lung-neuroendocrine-neoplasms/) and at the EMBL-EBI European Genome-phenome Archive and Gene Expression Omnibus data repositories. We provide data and all resources needed to integrate them with future LNENs transcriptomic studies, allowing meaningful conclusions to be drawn that will eventually lead to a better understanding of this rare understudied disease.

Sections du résumé

BACKGROUND
Lung neuroendocrine neoplasms (LNENs) are rare solid cancers, with most genomic studies including a limited number of samples. Recently, generating the first multi-omic dataset for atypical pulmonary carcinoids and the first methylation dataset for large-cell neuroendocrine carcinomas led us to the discovery of clinically relevant molecular groups, as well as a new entity of pulmonary carcinoids (supra-carcinoids).
RESULTS
To promote the integration of LNENs molecular data, we provide here detailed information on data generation and quality control for whole-genome/exome sequencing, RNA sequencing, and EPIC 850K methylation arrays for a total of 84 patients with LNENs. We integrate the transcriptomic data with other previously published data and generate the first comprehensive molecular map of LNENs using the Uniform Manifold Approximation and Projection (UMAP) dimension reduction technique. We show that this map captures the main biological findings of previous studies and can be used as reference to integrate datasets for which RNA sequencing is available. The generated map can be interactively explored and interrogated on the UCSC TumorMap portal (https://tumormap.ucsc.edu/?p=RCG_lungNENomics/LNEN). The data, source code, and compute environments used to generate and evaluate the map as well as the raw data are available, respectively, in a Nextjournal interactive notebook (https://nextjournal.com/rarecancersgenomics/a-molecular-map-of-lung-neuroendocrine-neoplasms/) and at the EMBL-EBI European Genome-phenome Archive and Gene Expression Omnibus data repositories.
CONCLUSIONS
We provide data and all resources needed to integrate them with future LNENs transcriptomic studies, allowing meaningful conclusions to be drawn that will eventually lead to a better understanding of this rare understudied disease.

Identifiants

pubmed: 33124659
pii: 5943495
doi: 10.1093/gigascience/giaa112
pmc: PMC7596803
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : R03 CA195253
Pays : United States

Informations de copyright

© World Health Organization, 2020. The World Health Organization has granted the Publisher permission for the reproduction of this article.

Références

Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Nat Commun. 2014 Mar 27;5:3518
pubmed: 24670920
Bioinformatics. 2014 May 15;30(10):1363-9
pubmed: 24478339
Nat Genet. 2012 Oct;44(10):1111-6
pubmed: 22941189
Bioinformatics. 2019 Feb 1;35(3):526-528
pubmed: 30016406
Biometrika. 1950 Jun;37(1-2):17-23
pubmed: 15420245
Genome Biol. 2016 Oct 7;17(1):208
pubmed: 27717381
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
Virchows Arch. 2018 Apr;472(4):567-577
pubmed: 29388013
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Am J Hum Genet. 2019 Jan 3;104(1):13-20
pubmed: 30609404
Cancer Res. 2019 Sep 1;79(17):4339-4347
pubmed: 31300474
Bioinformatics. 2015 Jun 15;31(12):2032-4
pubmed: 25697820
Sci Data. 2019 Jun 20;6(1):98
pubmed: 31222016
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Bioinformatics. 2012 Aug 15;28(16):2184-5
pubmed: 22743226
Biol Aujourdhui. 2017;211(3):233-237
pubmed: 29412134
Mod Pathol. 2018 Dec;31(12):1770-1786
pubmed: 30140036
Bioinformatics. 2019 Sep 1;35(17):2966-2973
pubmed: 30649250
Nat Commun. 2019 Aug 20;10(1):3407
pubmed: 31431620
Genome Biol. 2014;15(12):550
pubmed: 25516281
Bioinformatics. 2016 Jan 15;32(2):292-4
pubmed: 26428292
Nat Biotechnol. 2015 Mar;33(3):290-5
pubmed: 25690850
J Thorac Oncol. 2019 Sep;14(9):1651-1661
pubmed: 31085341
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Bioinformatics. 2014 Sep 1;30(17):2503-5
pubmed: 24812344
Nat Genet. 2012 Oct;44(10):1104-10
pubmed: 22941188
Clin Cancer Res. 2016 Jul 15;22(14):3618-29
pubmed: 26960398
Nature. 2015 Aug 6;524(7563):47-53
pubmed: 26168399
Nat Commun. 2018 Mar 13;9(1):1048
pubmed: 29535388
Curr Protoc Bioinformatics. 2013;43:11.10.1-11.10.33
pubmed: 25431634
Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S430-S434
pubmed: 32038931
Bioinformatics. 2014 Oct;30(19):2813-5
pubmed: 24907369
Cancer Res. 2017 Nov 1;77(21):e111-e114
pubmed: 29092953

Auteurs

Aurélie A G Gabriel (AAG)

Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69372 Lyon CEDEX 08, France.

Emilie Mathian (E)

Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69372 Lyon CEDEX 08, France.

Lise Mangiante (L)

Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69372 Lyon CEDEX 08, France.

Catherine Voegele (C)

Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69372 Lyon CEDEX 08, France.

Vincent Cahais (V)

Section of Mechanisms of Carcinogenesis, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69372 Lyon CEDEX 08, France.

Akram Ghantous (A)

Section of Mechanisms of Carcinogenesis, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69372 Lyon CEDEX 08, France.

James D McKay (JD)

Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69372 Lyon CEDEX 08, France.

Nicolas Alcala (N)

Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69372 Lyon CEDEX 08, France.

Lynnette Fernandez-Cuesta (L)

Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69372 Lyon CEDEX 08, France.

Matthieu Foll (M)

Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69372 Lyon CEDEX 08, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH